Friday, 16 October 2026European Markets

ATLANTIC SAPPHIRE Stock Over 27% Down In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ATLANTIC SAPPHIRE (Oslo Børs Benchmark Index_GI: ASA.OL) fell by a staggering 27.83% in 21 sessions from kr10.17 to kr7.34 at 13:27 EST on Monday, after five successive sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.91% to kr1,237.83, following the last session's downward trend.

About ATLANTIC SAPPHIRE

Atlantic Sapphire ASA, together with its subsidiaries, engages in the land-based salmon farming business. The company operates through two segments, Fish Farming (Denmark); and Fish Farming (US). It is involved in the production and sale of salmon. The company operates in the United States, Denmark, and internationally. Atlantic Sapphire ASA was founded in 2010 and is headquartered in Vikebukt, Norway.

Earnings Per Share

As for profitability, ATLANTIC SAPPHIRE has a trailing twelve months EPS of kr-6.16.

Volatility

ATLANTIC SAPPHIRE's last week, last month's, and last quarter's current intraday variation average was a negative 2.72%, a negative 1.78%, and a positive 3.99%.

ATLANTIC SAPPHIRE's highest amplitude of average volatility was 2.72% (last week), 2.88% (last month), and 3.99% (last quarter).

More news about ATLANTIC SAPPHIRE (ASA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com